---
title: "12:07 ETBioretec Ltd's Financial Statements and Annual Report 2025 published"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279070609.md"
description: "Bioretec Ltd has published its 2025 Financial Statements and Annual Report, available in Finnish and English on its website. The company specializes in biodegradable implant technologies for orthopedic care, with products used in around 40 countries. Their latest innovation, the RemeOs™ product line, received market authorization in the U.S. in March 2023 and CE mark approval in Europe in January 2025. Bioretec aims to enhance surgical outcomes and patient-friendly solutions in orthopedic treatment."
datetime: "2026-03-13T16:08:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279070609.md)
  - [en](https://longbridge.com/en/news/279070609.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279070609.md)
generator: "portal-rs"
---

# 12:07 ETBioretec Ltd's Financial Statements and Annual Report 2025 published

Bioretec Ltd | Company announcement | 13 March 2026 at 5:15 p.m.

, /PRNewswire/ -- Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release and also available in Finnish and English on the company's website at investors.bioretec.com/en/reports\_and\_presentations.

**For additional information:** 

Sarah van Hellenberg Hubar-Fisher, CEO  
+31 6 1544 8736  
\[email protected\]

Tuukka Paavola, CFO  
+358 50 386 0013  
\[email protected\]

**Certified Adviser**

Nordic Certified Adviser AB, +46 70 551 67 29

**Information about Bioretec**

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/bioretec/r/bioretec-ltd-s-financial-statements-and-annual-report-2025-published,c4321243

The following files are available for download:

https://mb.cision.com/Main/20509/4321243/3982609.pdf 

Bioretec ENG Financial Statements 2025

https://mb.cision.com/Public/20509/4321243/bbb2c0638dfa5aac.pdf 

Bioretec Annual Report 2025

### Related Stocks

- [BIORQ.US](https://longbridge.com/en/quote/BIORQ.US.md)
- [BIOR.US](https://longbridge.com/en/quote/BIOR.US.md)

## Related News & Research

- [Record Fee-Based Assets at Stifel Financial Might Change The Case For Investing In Stifel Financial (SF)](https://longbridge.com/en/news/297408464.md)
- [TDM Financial Retained for Investor Awareness Services](https://longbridge.com/en/news/297204289.md)
- [HRT Financial LP sells 15,788 Founder Group common shares for $3,536.51](https://longbridge.com/en/news/297358236.md)
- [EFG International AG Invests $1.05 Million in Synchrony Financial $SYF](https://longbridge.com/en/news/297145400.md)
- [LPL Financial Welcomes Preferred Financial Group | LPLA Stock News](https://longbridge.com/en/news/296919003.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**